Shareholders meeting

Date: August 31, 2026 BSE Limited National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai- 400001 Bandra (E) Scrip Code: 544292, Mumbai – 400 051 ISIN: INE013P01021 Symbol: ONESOURCE Dear Sir/ Madam, Subject: Notice of the 19th Annual General Meeting (AGM) and the Integrated Annual Report for the Financial Year 2025-26 This is to inform that the 19th AGM of the Company (2nd AGM after listing) is scheduled to be held on Wednesday, September 23, 2026, at 17:00 hours (IST) through video conferencing and OAVM. Pursuant to Section 108 of the Companies Act, 2013 and Regulations 30, 34 and 36 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following documents: Particulars Link Notice of the 19th AGM (including e-voting instructions) Click here Integrated Annual Report for the financial year 2025-26 Click here The aforesaid documents are available on the website of the Company at the above links and are being dispatched to all eligible Members of the Company whose email addresses are registered with the Company/ Depositories/ Registrar and Transfer Agent. This is for information and records. For and on behalf of OneSource Specialty Pharma Limited Trisha A Company Secretary and Compliance Officer Membership Number: A47635 Building for the Future INTEGRATED ANNUAL The new way to CDMO REPORT 2025-26 Across the Pages 02-132 Corporate Overview This is OneSource Value Creation Approach 2 Prelude 46 Value Creation Framework 12 About the Report 48 Stakeholder Engagement 14 FY26 Performance 50 Materiality Assessment 16 Big Picture 52 Strategic Priorities 18 About OneSource Capital-wise Progress 20 Service Offerings 56 Financial Capital Leadership Perspectives and Governance 60 Manufactured Capital 28 Founder and Chairperson’s Message 72 Intellectual Capital 30 Chief Executive Officer and Managing 84 Human Capital Director’s Message 96 Social and Relationship Capital 32 Chief Financial Officer’s Perspective 108 Natural Capital 36 Governance 116 Risk Management 40 Board of Directors 122 GRI Scorecard 44 Leadership Team 128 ESG Dashboard 131 Glossary 134-229 401-429 Statutory Reports AGM Notice 134 Management Discussion & Analysis 144 Board’s Report 430-436 164 Corporate Governance Report 187 Business Responsibility & Sustainability Report GRI Index 230-400 Financial Statements 230 Standalone Financial Statements 317 Consolidated Financial Statements To know more, please visit our website www.onesourcecdmo.com Prelude Our Journey Partnered with Pharmagel First USFDA approval for Divested Agila (Italy) to set up a soft Penicillin site to Mylan gelatin facility at KR Suresh Gardens (KRSG), in Bengaluru Biotech business re- branded as “Stelis Biopharma” 1990 1995 1998 2007 2010 2013 Rebranded Specialty (injectable) business as Agila Incorporation of Strides Commissioned first Pharmaceuticals soft gelatin facility at Acquired Private Limited KRSG, Bengaluru Inbiopro entering biologics space 2 OneSource Specialty Pharma Limited Corporate Overview Statutory Reports Financial Statements Drug Product (DP) Brand launch Expanding cartridge manufacturing at manufacturing capacity at our NCLT Mumbai sanctioned Unit-2 of Stelis integrated DS & DP facility Scheme of Arrangement; Biopharma got ₹8,010 million fundraise FDA approval 5 credit rating upgrades, from leading domestic and reaching the A category with international investors a Positive outlook 2020 2022 2023 2024 2025 2026 Stelis Biopharma divested Unit 3 to Syngene Scheme of Arrangement announced combining Strides’ Re-entered softgel business, Steriscience Listed on the National injectable business injectables, and Stelis Biopharma Stock Exchange (NSE) with Steriscience into OneSource, effective 1 and Bombay Stock April 2024 Exchange (BSE) Integrated Annual Report 2025-26 3 Prelude We are Building Long-term Customer Partnerships Our strategy is validated by 4 the customers who work with us, G7 Semaglutide Approvals deepen those relationships, and give us a growing share of their portfolios. Customers across 2+ Projects/Products What customers buy from us is more than manufacturing capacity. They rely on our scientific expertise, regulatory experience, and quality standards, enabling increasingly complex programmes to be consolidated with a single partner. As these programmes advance, customers Global Customers increasingly expand the scope of their engagement with us. The launch of semaglutide, first in India and subsequently in Canada, across multiple customer brands was a significant milestone, demonstrating our ability to execute complex peptide-based DDC programmes at scale. Today, all generic semaglutide approvals across the G7 have been secured through our partners. The strongest validation of our strategy is the trust customers place in us, reflected in long-term commitments and repeat business wins. 4 OneSource Specialty Pharma Limited Corporate Overview Statutory Reports Financial Statements We are Building a Strong Multi-Modality Platform We bring together four platforms to create a differentiated multi- modality offering for complex pharmaceutical needs. Our broad capabilities support a diverse range of molecules, dosage forms, and delivery systems across the product lifecycle, providing customers with a flexible and scalable platform for growth. 21 22 pg. pg. Biologics DDC 4x 50+ Increase in Biologics Funnel (YoY) DDC Projects 24 26 pg. pg. Sterile Injectables (excl. DDC) Oral Technologies (Soft gelatin capsules) Top 5 2.4 billion Penicillin Supplier to the US* Installed Softgel Capacity *In molecules being supplied to the US Our integrated platform combines capabilities across modalities, creating opportunities for growth and customer value across the pharmaceutical value chain. Integrated Annual Report 2025-26 5 Prelude We are Building Capacity with Discipline Our investments are focused on US$100 differentiated capabilities in million complex and high-value areas Announced Capex of pharmaceutical development and manufacturing, ahead of anticipated customer demand. Committed Capex Our platform has been built on more than US$250 million of investment across drug-device combinations (DDCs), Q2FY27 biologics, sterile injectables, and oral technologies. We direct capital where customer demand is strongest, our Second Cartridge Line Commercialisation capabilities most differentiated, and the potential for long-term value greatest. The majority of the current capex programme is going into cartridge capacity. The platform is designed to deliver scalable, long-term growth from differentiated capabilities and customer demand. 66 OOnneeSSoouurrccee SSppeecciiaallttyy PPhhaarrmmaa LLiimmiitteedd Corporate Overview Statutory Reports Financial Statements We are Building a Quality-First Organisation Quality is fundamental to 30+ years trust and long-term customer Quality and Operational Excellence relationships. Our aim is to build a quality-first 200+ organisation where quality is reflected in the way we operate, Successful Audits solve problems, and serve customers. 550+ Embedded across the organisation and the Employees in Quality Control and Assurance manufacturing lifecycle, quality guides decision- making, drives continuous improvement, and reinforces operational excellence. Our facilities are accredited by leading global regulatory authorities, including the USFDA, EMA, Health Canada, MHRA and WHO. Quality systems are supported by layered audits, digital quality management and continuous improvement programmes. We see quality as the foundation of customer and patient trust, reinforcing consistent execution, regulatory confidence, and product safety. IInntteeggrraatteedd AAnnnnuuaall RReeppoorrtt 22002255--2266 77 Prelude We are Building a High- Performance Organisation Our people are the foundation 1,600+ of our ability to deliver quality, Workforce execute complex progr [Showing first 8,000 characters — download PDF for full document]